Results 171 to 180 of about 54,594 (319)

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases [PDF]

, 2018
Michael A. Lyman, Vincent Lieuw, Robyn Richardson, Anjuli M. Timmer, Christine P. Stewart, Steve W. Granger, Richard Woods, Michela Silacci, Dragan Grabulovski, Roland Newman   +9 more
openalex   +1 more source

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E. Croteau   +3 more
wiley   +1 more source

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. [PDF]

Front Immunol
Paulsen JS, Slørdahl TS.
europepmc   +1 more source

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia A in paediatric patients presents a lifelong risk of spontaneous and trauma‐induced haemorrhage, leading to progressive joint damage, disability and impaired quality of life. Emicizumab, a bispecific monoclonal antibody administered subcutaneously, offers sustained haemostatic protection and has shown promising ...
Konstantina Bolou, George Triantafyllou, Athina Dettoraki, Aikaterini Michalopoulou, Miltiades Kyprianou, Olympia Papakonstantinou, Helen Pergantou   +6 more
wiley   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Bispecific antibodies: advancing precision oncology.

Trends in Cancer
Mercedes Herrera, Giulia Pretelli, Jayesh Desai, E. Garralda, L. Siu, T. M. Steiner, Lewis Au   +6 more
semanticscholar   +1 more source

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry

Haemophilia, EarlyView.
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen, Anthony K. C. Chan, Davide Matino, Emma Iserman, Arun Keepanasseril, Karen Strike   +5 more
wiley   +1 more source

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source

Bispecific antibody drug conjugates: Making 1+1>2

Acta Pharmaceutica Sinica B
Yilin Gu, Zhijia Wang, Yuxi Wang
semanticscholar   +1 more source